Peptide News Digest

Axios/Chainalysis: Chinese Fentanyl Makers Pivot to Peptides ($27M Q1 Crypto Payments), Kalohexis Files Confidential IPO on MC3R/MC4R Melanocortin Obesity Program, FDA 23 Novel Drug Approvals Through June Match Best First-Half Since 2023 Despite Staff Cuts, Vera Therapeutics Trutakna (Atacicept) IgA Nephropathy Accelerated Approval, PCAC Written-Comment Docket Closes Tomorrow for Member Review

Axios: Chinese fentanyl makers pivot to peptides; Kalohexis IPO on MC3R/MC4R obesity; FDA 23 novel approvals; Vera Trutakna approved; PCAC comment cutoff Jul 9.

5 stories · Covering industry, regulatory

Editor's Note

Wednesday's digest tracked a supply-chain shift that the FDA staff briefing documents last week hinted at but did not name directly. Axios reported Tuesday July 7 that Chainalysis blockchain analysis identified Chinese fentanyl-precursor manufacturers pivoting to the gray-market peptide trade: crypto payments to gray-market peptide vendors reached $27 million in Q1 2026, up nearly 150% from Q4 2025. One China-based company previously identified through its digital wallet as selling fentanyl precursors reappeared on message boards selling cosmetic and weight-loss peptides. Chainalysis analyst Sara Graham called the shift 'a business decision' by manufacturers moving from a sanctionable trade to a lucrative gray-market scene. Adjacent industry news: Kalohexis, the melanocortin-obesity biotech spun out of Endevica Bio in March 2026, filed a confidential IPO on the strength of its MC3R/MC4R dual-activation platform (Phase 1 oral 710GO in general obesity, Phase 2 mifomelatide in cancer cachexia). FDA cleared 23 novel drugs through June 30 despite April 2025 staff cuts, the best first half since 2023 (Endpoints News). Vera Therapeutics received FDA accelerated approval July 7 for Trutakna (atacicept), a BAFF/APRIL fusion protein for primary IgA nephropathy that cut proteinuria 45.7% versus 6.8% for standard of care at 36 weeks. And the PCAC written-comment docket FDA-2025-N-6895 closes Thursday July 9 for advisory-committee-member review ahead of the July 23-24 hearing on BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, and Epitalon.

Industry

Axios (July 7): Chinese Fentanyl Precursor Manufacturers Pivot to Gray-Market Peptide Sales, Per Chainalysis Blockchain Analysis: Q1 2026 Crypto Payments to Gray-Market Peptide Vendors Reached $27 Million, Up Nearly 150% From Q4 2025

Axios reported Tuesday July 7, 2026 that blockchain analysis firm Chainalysis has identified a supply-chain shift in which Chinese manufacturers of fentanyl chemical precursors are pivoting into the US gray-market peptide trade. Q1 2026 crypto payments to gray-market peptide vendors reached $27 million, up nearly 150% from Q4 2025. One China-based company previously identified through its digital cryptocurrency wallet as a seller of fentanyl precursors reappeared on message boards selling cosmetic and weight-loss peptides. Chainalysis senior intelligence analyst Sara Graham characterized the shift bluntly: 'For these manufacturers that decided to pivot, it was really a business decision. They departed from a trade in which they could be sanctioned or indicted by the US and reappeared in a very lucrative scene that has widespread buy-in.' The pivot happens against a regulatory backdrop where compounded GLP-1 supply through 503B outsourcing facilities is closing (FDA proposed permanent exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulks list on April 30, 2026), pushing gray-market demand toward alternative channels. Traditional US banks and credit-card processors decline the peptide-vendor transactions, so crypto has become the dominant payment rail. The Chainalysis findings extend the earlier Fortune June 4 piece on the $100 million gray-market looksmaxxing peptide economy.

#chainalysis #china #fentanyl-precursors #gray-market #cryptocurrency #sara-graham #peptide-supply-chain #axios
Industry

Kalohexis Files Confidential IPO Three Months After Endevica Bio Spinoff: Melanocortin-Obesity Biotech Advances Oral MC3R/MC4R Dual-Agonist 710GO in Phase 1 for General Obesity, With Mifomelatide MC3R/MC4R Antagonist in Phase 2 for Cancer Cachexia

Kalohexis, the melanocortin-receptor peptide biotech spun out of Endevica Bio in March 2026, filed a confidential IPO application with the SEC this week. The company advances two lead assets on the melanocortin platform: 710GO, an oral dual MC3R/MC4R agonist that entered Phase 1 testing in Q2 2026 for general obesity; and mifomelatide, a dual MC3R/MC4R antagonist in Phase 2 development for cancer cachexia (severe weight loss and muscle wasting in patients with advanced cancer). The two programs run in opposite pharmacological directions on the same receptor family: 710GO activates MC3R/MC4R to reduce food intake and produce weight loss; mifomelatide blocks MC3R/MC4R to reverse cachexia-driven weight loss. Kalohexis's Nature Communications publication (June 2026) demonstrated that dual MC3R/MC4R activation drove substantial weight loss and reduced food intake in nonhuman primates without the cardiovascular safety risks that limited earlier melanocortin drug candidates. Data was also presented at ENDO 2026. The IPO filing signals investor appetite for non-GLP-1 obesity mechanisms as the melanocortin pathway becomes the highest-profile alternative to incretin biology.

#kalohexis #endevica-bio #melanocortin #mc3r #mc4r #710go #mifomelatide #cancer-cachexia #obesity #confidential-ipo
Regulatory

FDA 23 Novel Drug Approvals Through June 30, 2026: Best First Half Since 2023 Despite April 2025 Staff Cuts, With 79 Total Regulatory Verdicts in H1 2026 Versus 85 in H1 2025; Novel Approvals Rose From 19 in H1 2025 to 26 by Endpoints News Count

Endpoints News published a mid-year FDA review Wednesday reporting that the FDA cleared 23 novel drugs through June 30, 2026, the best first half of a year for novel approvals since 2023. The pace held up despite the Trump administration's April 2025 FDA staff cuts that industry observers had feared would slow the approval machine. Total regulatory verdicts in H1 2026 ran 79 (slight decrease from 85 in H1 2025), but novel approvals ticked up substantially from 19 in H1 2025 to 26 by the Endpoints tally (approaches vary slightly by definition; the FDA's Novel Drug Approvals for 2026 tracker shows 23 through the June 30 cutoff). Approvals during the period spanned oncology, infectious disease, nephrology, dermatology, ophthalmology, and metabolic disease. The peptide-relevant approvals within this pace include Yuviwel (navepegritide, Ascendis Pharma's once-weekly C-type natriuretic peptide prodrug for pediatric achondroplasia; accelerated approval February 27), Foundayo (orforglipron, Eli Lilly's oral small-molecule GLP-1 for chronic weight management; April 1), Tryngolza (olezarsen, Ionis's ASO for severe hypertriglyceridemia; June 24), and Trutakna (atacicept, Vera Therapeutics' BAFF/APRIL fusion protein for IgA nephropathy; July 7). The staff-cut concern has partially receded, though longer-term impacts on Center for Drug Evaluation and Research (CDER) throughput remain a Q3-Q4 2026 story to watch.

#fda #novel-drug-approvals #endpoints-news #cder #staff-cuts #yuviwel #foundayo #tryngolza #trutakna #h1-2026
Regulatory

FDA Grants Accelerated Approval for Vera Therapeutics' Trutakna (Atacicept-Vymj) for Adult Patients with Primary IgA Nephropathy on Tuesday July 7: BAFF/APRIL-Targeting Fusion Protein Cut Proteinuria 45.7% Versus 6.8% for Standard of Care Alone at 36 Weeks in the ORIGIN Phase 3 Trial

The FDA granted accelerated approval Tuesday July 7, 2026 to Trutakna (atacicept-vymj) for adult patients with primary IgA nephropathy (IgAN) at risk of rapid disease progression, in combination with standard of care. Vera Therapeutics developed the drug as a recombinant fusion protein that combines the extracellular domain of the transmembrane activator and CAML interactor (TACI) receptor with the Fc portion of human IgG1, binding both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) to reduce autoantibody-driven kidney damage. The registrational Phase 3 ORIGIN trial data supporting approval: at 36 weeks, Trutakna plus standard of care produced a 45.7% reduction in urine protein-to-creatinine ratio versus a 6.8% reduction for standard of care alone. IgA nephropathy affects approximately 130,000 to 150,000 Americans and is the most common primary glomerular disease worldwide; approximately 40% of patients progress to end-stage renal disease within 20 years without adequate treatment. Trutakna is a fusion protein rather than a peptide but sits in adjacent therapeutic territory relevant to the site's peptide-and-biologic coverage. Vera Therapeutics (NASDAQ: VERA) is expected to launch the product in Q3 2026. Continued approval may be contingent on verification of clinical benefit in confirmatory Phase 3 studies.

#vera-therapeutics #trutakna #atacicept #iga-nephropathy #baff #april #fusion-protein #accelerated-approval #origin-trial
Regulatory

PCAC Written-Comment Docket FDA-2025-N-6895 Closes Thursday July 9 at 11:59 PM ET for Advisory-Committee Member Review Ahead of the July 23-24 Meeting on BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, and Epitalon; Hard Deadline for All Written Submissions Remains July 22

The FDA Pharmacy Compounding Advisory Committee written-comment docket FDA-2025-N-6895 reaches its first procedural cutoff Thursday July 9, 2026 at 11:59 PM ET. Comments submitted by this deadline will be formally provided to PCAC members ahead of the July 23-24 meeting. Written submissions after July 9 remain on the record but reach members after their initial review preparation. The docket's absolute hard deadline for all written comment submissions is July 22, 2026 at 11:59 PM ET (one day before the meeting opens). Compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer advocacy voices (Public Citizen), academic researchers (UC Davis's Paul Knoepfler), and individual physicians have filed comments across both the pro-approval and pro-restriction sides of the panel decision. The FDA career-staff briefing documents (released June 29-30) concluded all seven peptides have insufficient evidence for 503A bulks list eligibility, citing immunogenicity concerns, heavy-metal and microbial contamination in compounded product samples, mislabeled contents, and thin 503A historical use. The July 9 threshold is the operational moment at which panelists get their reading pile; the record they use to deliberate the July 23-24 vote is set today.

#pcac #fda #docket #written-comments #bpc-157 #kpv #tb-500 #mots-c #emideltide #semax #epitalon #advisory-committee